OGEN Oragenics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: OGEN

Price (delayed)

$1.08

Market cap

$4.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.18

Enterprise value

$1.68M

Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against ...

Highlights
The debt has declined by 48% year-on-year and by 38% since the previous quarter
Oragenics's net income has plunged by 104% from the previous quarter and by 45% YoY
OGEN's EPS has dropped by 97% since the previous quarter and by 29% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oragenics.com
Peers: PRPH OPK USNA NATR

Key stats

What are the main financial stats of OGEN
Market
Shares outstanding
4.48M
Market cap
$4.84M
Enterprise value
$1.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.88
Price to sales (P/S)
64.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
44.57
Earnings
Revenue
$37,653
EBIT
-$20.63M
EBITDA
-$20.6M
Free cash flow
-$7.23M
Per share
EPS
-$9.18
Free cash flow per share
-$3.21
Book value per share
$1.23
Revenue per share
$0.02
TBVPS
$2.21
Balance sheet
Total assets
$4.97M
Total liabilities
$1.8M
Debt
$322,514
Equity
$3.17M
Working capital
$2.07M
Liquidity
Debt to equity
0.1
Current ratio
2.15
Quick ratio
1.94
Net debt/EBITDA
0.15
Margins
EBITDA margin
-54,704.2%
Gross margin
100%
Net margin
-54,858.1%
Operating margin
-55,519.9%
Efficiency
Return on assets
-246.9%
Return on equity
-304.1%
Return on invested capital
-2,094.2%
Return on capital employed
-651%
Return on sales
-54,776.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OGEN stock price

How has the Oragenics stock price performed over time
Intraday
0%
1 week
-10%
1 month
-22.86%
1 year
-66.87%
YTD
-80.8%
QTD
-25%

Financial performance

How have Oragenics's revenue and profit performed over time
Revenue
$37,653
Gross profit
$37,653
Operating income
-$20.9M
Net income
-$20.66M
Gross margin
100%
Net margin
-54,858.1%
The net margin has dropped by 104% since the previous quarter
Oragenics's net income has plunged by 104% from the previous quarter and by 45% YoY
OGEN's operating income has dropped by 101% since the previous quarter and by 45% year-on-year
The operating margin has plunged by 101% from the previous quarter

Growth

What is Oragenics's growth rate over time

Valuation

What is Oragenics stock price valuation
P/E
N/A
P/B
0.88
P/S
64.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
44.57
OGEN's EPS has dropped by 97% since the previous quarter and by 29% year-on-year
Oragenics's equity has plunged by 76% YoY and by 51% from the previous quarter
The P/B is 58% less than the 5-year quarterly average of 2.1 and 51% less than the last 4 quarters average of 1.8
Oragenics's revenue has shrunk by 71% YoY
The stock's price to sales (P/S) is 59% less than its last 4 quarters average of 157.4

Efficiency

How efficient is Oragenics business performance
OGEN's ROE has plunged by 177% from the previous quarter
OGEN's ROA has dropped by 163% since the previous quarter
The company's return on invested capital has shrunk by 109% YoY
OGEN's return on sales has dropped by 104% since the previous quarter

Dividends

What is OGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OGEN.

Financial health

How did Oragenics financials performed over time
The total assets is 176% more than the total liabilities
Oragenics's current ratio has shrunk by 76% YoY and by 61% QoQ
The company's quick ratio has shrunk by 73% YoY and by 53% QoQ
The debt is 90% smaller than the equity
OGEN's debt to equity has soared by 100% YoY and by 25% QoQ
Oragenics's equity has plunged by 76% YoY and by 51% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.